Clerk of the House of Representatives Secretary of the Senate Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Office of Public Records 232 Hart Building Washington, DC 20510

SECRETARY OF T 02 FEB 15

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Abbott Laboratories			.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2. Address Check if different t	han previously reported		
1710 Rhode Island Ave., เ	N.W., Suite 300 . Washing	ton, DC 20036	
3. Principal Place of Business (if differ	ent from line 2)	***************************************	
City: Abbott Park	State/	Zip (or Country) Illinois 60064	
Contact Name	Telephone	E-mail (optional)	5. Senate ID#
Cynthia B. Sensibaugh	(202) 659-8524	cynthia.sensibaugh@abbot	t.com 66
Client Name 🗹 Self			6. House ID#
Self :			3000
Check if this filing amends a p	oreviously filed version of this Report	Date	11. No Lobbyin
Check if this filing amends a p	reviously filed version of this Report	Date	
Check if this filing amends a positive of this is a Termination of the company of	reviously filed version of this Report □ ⇔ Termination NSES - Complete Either ing Firms	Date Line 12 OR Line 13	ations
Check if this filing amends a process of this is a Termination of the Company of	reviously filed version of this Report □ ⇔ Termination NSES - Complete Either ing Firms	Line 12 OR Line 13 13. Organiza EXPENSES relating to lobbying active	ations
Check if this filing amends a process. Check if this is a Termination INCOME OR EXPERIMENTAL Lobby INCOME relating to lobbying period was:	reviously filed version of this Report □ ⇔ Termination NSES - Complete Either ing Firms	Line 12 OR Line 13 13. Organiza EXPENSES relating to lobbying acti period were: Less than \$10,000 \$10,000 or more \$\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overli	ations vities for this rep
Check if this filing amends a process of this is a Termination INCOME OR EXPERIMENTAL Lobby INCOME relating to lobbying speriod was:	reviously filed version of this Report □ ⇔ Termination NSES - Complete Either ing Firms	Line 12 OR Line 13 13. Organiza EXPENSES relating to lobbying actiperiod were: Less than \$10,000 \$10,000 or more \$\omega\$ \$\square\$	ations vities for this rep 0,000.00 enses (nearest \$20,0
Check if this filing amends a positive of the content of the conte	reviously filed version of this Report □ ⇔ Termination NSES - Complete Either ing Firms activities for this reporting Income (nearest \$20,000)	Line 12 OR Line 13 13. Organiza EXPENSES relating to lobbying acti period were: Less than \$10,000 \$10,000 or more \$\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overline{\overli	otions vities for this report of the second
Check if this filing amends a process of the content of the conten	reviously filed version of this Report □ ⇒ Termination NSES - Complete Either ing Firms activities for this reporting Income (nearest \$20,000) unded to the nearest \$20,000, from the client (including all	Line 12 OR Line 13 13. Organiza EXPENSES relating to lobbying actiperiod were: Less than \$10,000 \$10,000 or more \$\simeq\$ \$\simeq\$ \$\frac{1}{46}\$ Expenses \$\frac{1}{46}\$ Expenses \$\frac{1}{46}\$ Check the state of the st	o, 000.00 enses (nearest \$20,000 to description o
INCOME relating to lobbying period was: Less than \$10,000	reviously filed version of this Report □ ⇒ Termination NSES - Complete Either ing Firms activities for this reporting Income (nearest \$20,000) unded to the nearest \$20,000, from the client (including all any other entity for lobbying	Line 12 OR Line 13 13. Organiza EXPENSES relating to lobbying actiperiod were: Less than \$10,000 \$10,000 or more \$\simegar{\text{\text{\$\sigma}}} \prescript{\text{\$\sigma}} \pres	o, 000.00 consess (nearest \$20,00) ck box to indicate for description of the section 603

Registrant Name	Abbott Laboratories	Client Namė		Self
Information Up	date Page - Complete ON	LY where registration inf	ormation has	changed.
20. Client new address				
	place of business (if different from lin		*************************	
City		State/Zip (or Country)	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
22. New general descript	tion of client's business or activities			
LOBBYIST UPD	ATE eviously reported individual w	the is no longer expected t	o act as a lobb	vict for the client
Francis X. Tirrell		no is no longer expected to	y act as a 1000	yist for the chefit
Ý				
AFFILIATED OR 25. Add the followin	g affiliated organization(s)	Address		Principal Place of E (city and state or c
26.27				
20. Name of each pro	eviously reported organization	that is no longer attiliated	with the regis	trant or client
FOREIGN ENTITIE 7. Add the following				
Name	Address		ce of business e or country)	Amount of contribution for lobbying activities
			••••	
28. Name of each pre affiliated organiz	eviously reported foreign entity exation	that no longer owns, or co	ontrols, <u>or</u> is a	ffiliated with the registr
ij V				
gnature !			Date	

Printed Name and Title	
Form LD-2 (Rev. 6/98)	Page 2
	· · · · · · · · · · · · · · · · · · ·

Registrant Name	Abbott Laboratories	Client Name	Self
engaged in lobbying		ing the reporting period	et the general issue areas in which the r . Using a separate page for each code
15. General issue ar	rea code BUD (on	e per page)	
16. Specific lobbyir	ng issues		
		ons FY 2002, funding for W	omen, Infants and Children program.
2. H.R. 3061, S. the Rýan White A		ions FY 2002, funding for si	tate AIDS Drug Assistance programs under
17. House(s) of Cor	ngress and Federal agencies	s contacted	Check if None
House			
Senate			
() () () () () () () () () ()			,
18. Name of each in	ndividual who acted as a lo	bbyist in this issue area	
		ı	
	Name		Covered Official Position (if applicable)
Mark E. Barmak			
Elaine R. Leavenwor	th		
Rosemary T. Haas			

			·,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
			······································
#			
(
19. Interest of each fo	reign entity in the specific iss	ues listed on line 16 above	☐ Check if None
ξ.			
Signature			Date
Printed Name and Title	Filing #4d844163-e890-4473	-ba5e-303e596df340 - Pag	e 5 of 16

Page _3

Form LD-2 (Rev.6/98)

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each coinformation as requested. Attach additional page(s) as needed. 15. General issue area code HCR (one per page) 16. Specific lobbying issues 1. iH.R. 2330, S. 1191 - Agriculture Appropriations FY 2002, amendment concerning reimportation of prescription does 2. iH.R. 526, S. 1052 - Patients' Bill of Rights 3. iH.R. 2887, H.R. 3452, S. 338, S. 1789 - Best Pharmaceuticals for Children Act 4. FDA review, Inspection and enforcement activities 17. House(s) of Congress and Federal agencies contacted Check if None House Senate Food and Drug Administration Health and Human Services - Office of the Secretary 18. Name of each individual who acted as a lobbyist in this issue area. Name Covered Official Position (if applicable) Mark E. Barmak Eleine R. Lesverworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above Date Date	Registrant Name	Abbott Laboratories	Client Name	Self
16. Specific lobbying issues 1. iH.R. 2330, S. 1191 - Agriculture Appropriations FY 2002, amendment concerning reimportation of prescription of 2. iH.R. 526, S. 1052 - Patients' Bill of Rights 3. iH.R. 2867, H.R. 3452, S. 838, S. 1789 - Best Pharmaceuticals for Children Act 4. FDA review, Inspection and enforcement activities 17. House(s) of Congress and Federal agencies contacted ☐ Check if None House Senate Food and Drug Administration Health and Human Services - Office of the Secretary 18. Name of each individual who acted as a lobbyist in this issue area Name ☐ Covered Official Position (if applicable) Mark E. Barmak Elaine R. Leavenworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above ☑ Check if None	engaged in lobbying	on behalf of the client dur	ing the reporting period. U	
1. H.R. 2330, S. 1191 - Agriculture Appropriations FY 2002, amendment concerning reimportation of prescription of 2. H.R. 526, S. 1052 - Patients' Bill of Rights 3. H.R. 2887, H.R. 3452, S. 838, S. 1789 - Best Pharmaceuticals for Children Act 4. FDA review, Inspection and enforcement activities 17. House(s) of Congress and Federal agencies contacted	15. General issue are	ea code HCR (on	e per page)	
2. H.R. 526, S. 1052 - Patients' Bill of Rights 3. H.R. 2887, H.R. 3452, S. 838, S. 1789 - Best Pharmaceuticals for Children Act 4. FDA review, Inspection and enforcement activities 17. House(s) of Congress and Federal agencies contacted House Senate Food and Drug Administration Health and Human Services - Office of the Secretary 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Mark E. Barmak Elaine R. Leavenworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above		-	one EV 2002, amendment cond	perning reimportation of prescription dr
3. H.R. 2887, H.R. 3452, S. 838, S. 1789 - Best Pharmaceuticals for Children Act 4. FDA review, Inspection and enforcement activities 17. House(s) of Congress and Federal agencies contacted	•		mo i i zooz, amendment cone	coming reimportation of pressilption are
17. House(s) of Congress and Federal agencies contacted	,	•	t Pharmaceuticals for Children	Act
House Senate Food and Drug Administration Health and Human Services - Office of the Secretary 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Mark E. Barmak Elaine R. Leavenworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above	4. FDA review, In	spection and enforcement act	ivities	
Senate Food and Drug Administration Health and Human Services - Office of the Secretary 18. Name of each individual who acted as a lobbyist in this issue area Name Covered Official Position (if applicable) Mark E. Barmak Elaine R. Leavenworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above	17. House(s) of Con	gress and Federal agencie	s contacted	neck if None
Name Covered Official Position (if applicable) Mark E. Barmak Elaine R. Leavenworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above	Senate Food and Drug		Secretary	
Mark E. Barmak Elaine R. Leavenworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above	18. Name of each in	dividual who acted as a lo	bbyist in this issue area	
Elaine R. Leavenworth Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None		Name		Covered Official Position (if applicable)
Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above	Mark E. Barmak			
Cynthia B. Sensibaugh Rosemary T. Haas Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above				
Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None	Cynthia B. Sensibaug	jh		
Francis X. Tirrell 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None	Rosemary T. Haas			
19. Interest of each foreign entity in the specific issues listed on line 16 above	∜ Francis X. Tirrell			
19. Interest of each foreign entity in the specific issues listed on line 16 above	\ \			
19. Interest of each foreign entity in the specific issues listed on line 16 above	i .			
	· · · · · · · · · · · · · · · · · · ·	······································		
SignatureDate	19. Interest of each fo	reign entity in the specific is	l sues listed on line 16 above	Check if None
Signature Date	•			
	Signature			Date

Form LD-2 (Rev.6/98)
Page

Registrant	Name Abbott Laboratories	Client Name	Self
engaged i		during the reporting period.	et the general issue areas in which the : . Using a separate page for each code
15. Gene	al issue area code MMM	(one per page)	
	fic lobbying issues		
2. S. 3. S. 4. H.I 5. H.I 6. H.I	R. 1624, S. 913 - Access to Cancer T 357 - Medicare Preservation and Imp 358 - Medicare Prescription Drug and R. 1089, S. 554 - Access to Innovatio R. 1798, S. 1066 - Medicare Patient A R. 2768, H.R. 3046, H.R. 3391 - Medi ds for determining payment basis for dicare coverage of anti-obesity drugs	rovement Act of 2001 I Modernization Act of 2001 In for Medicare Patients Act of 20 Inccess Preventive and Diagnosticare Regulatory and Contracting Inew lab tests	001 ic Tests Act g Reform Act of 2001, provision relating to
17. House	e(s) of Congress and Federal age	ncies contacted	Check if None
Cent		rvices	
	Name		Covered Official Position (if applicable)
Mark E. E	armak		***************************************
Elaine R.	Leavenworth		
Cynthia E	. Sensibaugh		
Roseman	T. Haas	-	
Francis X	Tirrell		
***************************************	1	***************************************	4 7 7
******************		,	
***************************************		•••••••••••••••••••••••••••••••••••••••	
19. Interes	of each foreign entity in the specifi	l c issues listed on line 16 above	☑ Check if None
Signature_			Date

¢ k		·	
Form LD-2 (Rev.6/98)		•	ſ
}			·

Registrant Name	Abbott Laboratories	Client Name	Self
engaged in lobbying		ng the reporting period.	t the general issue areas in which the re Using a separate page for each code.
15. General issue are	ea code MMM (cont)(one	e per page)	
16. Specific lobbyin		Castline Fleride and Rear	and coin to and an arisely assess that
vitamin D therapy			nyslvania to reduce reimbursement for
9. H _. R. 3061, S. 1 government pricin		ons FY 2002, amendment ex	xpanding entities eligible for favorable
10. Ensure adequ	ate Medicare reimbursement f	or new technologies to incre	ease the safety of the blood supply
17. House(s) of Con	gress and Federal agencies	contacted	Check if None
	an Services - Office of the sicare and Medicaid Service		
18. Name of each in	dividual who acted as a lob	byist in this issue area	
Mark E. Barmak	Name		Covered Official Position (if applicable)
Elaine R. Leavenwort	h		
Cynthia B. Sensibaug	h		······································
Rosemary T. Haas			
Francis X. Tirrell			

19. Interest of each for	eign entity in the specific issu	es listed on line 16 above	Check if None
ļ :			
Signature !			D.

Triffico Ivallic and Trife	
•	
Form LD-2 (Rev.6/98)	Page <u>6</u>

Registrant Name	Abbott Laboratories	Client Name	Self
engaged in lobbying		ing the reporting period.	t the general issue areas in which the re Using a separate page for each code,
15. General issue a	rea code <u>TAX</u> (on	e per page)	
16. Specific lobbyin	ng issues	of 2001	- Ad
		. `	
<u> </u>	igress and Federal agencies	contacted	Check if None
House Senate Senate 18. Name of each in	dividual who acted as a lob	byist in this issue area	
Mark E. Barmak	Name		Covered Official Position (if applicable)
Elaine R. Leavenwort		***************************************	
Rosemary T. Haas			
19. Interest of each for	eign entity in the specific issue	es listed on line 16 above	Check if None
({			•
Signature	•		Date

Printed (Name and 1)tile	
Form LD-2 (Rev.6/98)	Page <u>7</u>

Registrant Name	Abbott Laboratories	Client Name	Self
engaged in lobbying	ITY. Select as many code on behalf of the client during ted. Attach additional pag	ng the reporting period	ect the general issue areas in which the
15. General issue are	ea code TRD (one	per page)	
16. Specific lobbying	g issues		
1. H.R. 1786, S. 8	47 - To impose tariffs on certai	n casein and milk proteir	n concentrates
17. House(s) of Cong	gress and Federal agencies	contacted	Check if None
Senate 18. Name of each inc	dividual who acted as a lob	byist in this issue area	ı
; (5	Name		Covered Official Position (if applicable)
Mark E. Barmak			
Elaine R. Leavenwort	h		
Rosemary T. Haas	***************************************		
) ;			
v ř			
-			· ·
,		•••••••••••••••••••••••••••••••••••••••	***************************************
19. Interest of each for	eign entity in the specific issu	es listed on line 16 abov	e 🛮 Check if None
Signature UN	thia B. Sensil	panch	Date 2/15/02